+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Colorectal Cancer Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Chemotherapy, Immunotherapy), By Region (North America, Asia Pacific, Latin America, Europe), And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 100 Pages
  • September 2023
  • Region: Global
  • Grand View Research
  • ID: 5893108
Description Jump to:
The global colorectal cancer therapeutics market size is expected to reach USD 16.7 billion by 2030., exhibiting a CAGR of 4.7% from 2023 to 2030. Several factors such as increasing target population and rising adoption of targeted therapies are anticipated to fuel market growth.

Products in the pipeline are striving to meet some of the unmet needs of the colorectal cancer (CRC) market. If approved, Array Biopharma’s cetuximab plus encorafenib would become the first therapy indicated for BRAF-mutant mCRC treatment. Sumitomo Dainippon’s Napabucasin is a cancer stem cell inhibitor targeting STAT-3.

There are few available adjuvant/neoadjuvant medicines for treatment of high-risk resectable colorectal cancer. Lack of pipeline agents in this setting presents a good opportunity for development of effective treatments that can improve cure rates for resected patients. At present, most available treatments for resectable CRC include cheaper chemotherapeutic regimens and generics.

Upcoming patent expiries of key products such as Roche’s Avastin, Amgen’s Vectibix, and Sanofi’s Zaltrap will lead to biosimilar penetration. Amgen/Allergan’s Mvasi marked the first Avastin biosimilar approval in U.S. and Europe in 2017 and 2018, respectively. Cizumab and Krabeva are some of the biosimilars to Avastin launched in India. Several other biosimilars to Avastin and Erbitux are under development.

Colorectal Cancer Therapeutics Market Report Highlights

  • Immunotherapy dominated the market based on drug class in 2022, owing to increasing adoption of targeted therapies such as Avastin and Erbitux
  • Chemotherapy is likely to lose market share on account of non-specificity, adverse effects, and development of resistance to chemical agents. However, recent launch of anti-PD1 drugs such as Opdivo and Keytruda is likely to change the current landscape due to their target-oriented mechanism of action
  • U.S. accounted for the largest share based on country and is projected to maintain its dominance through to 2022 owing to growing disease burden, increasing treatment rate, and high cost of drugs
  • Roche led the colorectal cancer industrial setting in 2022 due to growing usage of Avastin. Avastin was the highest revenue-generating CRC medicine in 2022. However, Roche is projected to lose market share on grounds of Avastin’s patent expiry and biosimilar penetration
  • Bristol-Myer Squibb and Merck are anticipated to be market leaders in the colorectal cancer drugs market space by 2022 due to increasing adoption of targeted therapies such as Opdivo and Keytruda.


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Drug class
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug class outlook
2.2.2. Regional outlook
2.3. Competitive Insights
Chapter 3. Colorectal Cancer Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.2. Market Restraint Analysis
3.4. Colorectal Cancer Therapeutics Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic Landscape
Chapter 4. Colorectal Cancer Therapeutics Market: Drug Class Estimates & Trend Analysis
4.1. Colorectal Cancer Therapeutics Market: Key Takeaways
4.2. Colorectal Cancer Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Chemotherapy
4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Immunotherapy
4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Others
4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Colorectal Cancer Therapeutics Market: Regional Estimates & Trend Analysis
5.1. Regional Outlook
5.2. Colorectal Cancer Therapeutics Market by Region: Key Takeaway
5.3. North America
5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.3.2. U.S.
5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.3.3. Canada
5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4. Europe
5.4.1. UK
5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.2. Germany
5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.3. France
5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.4. Italy
5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.5. Spain
5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.6. Denmark
5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.7. Sweden
5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.8. Norway
5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5. Asia Pacific
5.5.1. Japan
5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.2. China
5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.3. India
5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.4. Australia
5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.5. Thailand
5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.6. South Korea
5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.6. Latin America
5.6.1. Brazil
5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.6.2. Mexico
5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.6.3. Argentina
5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.7. MEA
5.7.1. South Africa
5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.7.2. Saudi Arabia
5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.7.3. UAE
5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.7.4. Kuwait
5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Market Participant Categorization
6.2.1. Amgen, Inc.
6.2.1.1. Company Overview
6.2.1.2. Financial performance
6.2.1.3. Product benchmarking
6.2.1.4. Strategic initiatives
6.2.2. Bayer AG
6.2.2.1. Company overview
6.2.2.2. Financial performance
6.2.2.3. Product benchmarking
6.2.2.4. Strategic initiatives
6.2.3. Bristol-Myers Squibb Company
6.2.3.1. Company overview
6.2.3.2. Financial performance
6.2.3.3. Product benchmarking
6.2.3.4. Strategic initiatives
6.2.4. Lilly
6.2.4.1. Company overview
6.2.4.2. Financial performance
6.2.4.3. Product benchmarking
6.2.4.4. Strategic initiatives
6.2.5. Merck & co., Inc.
6.2.5.1. Company overview
6.2.5.2. Financial performance
6.2.5.3. Product benchmarking
6.2.5.4. Strategic initiatives
6.2.6. F. Hoffmann-La Roche Ltd
6.2.6.1. Company overview
6.2.6.2. Financial performance
6.2.6.3. Product benchmarking
6.2.6.4. Strategic initiatives
6.2.7. Sanofi
6.2.7.1. Company overview
6.2.7.2. Financial performance
6.2.7.3. Product benchmarking
6.2.7.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 North America colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 3 North America colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
Table 4 U.S. colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 5 Canada colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 6 Europe colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 7 Europe colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
Table 8 Germany colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 9 UK colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 10 France colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 11 Italy colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 12 Spain colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 13 Sweden colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 14 Norway colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 15 Denmark colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 16 Asia Pacific colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 17 Asia Pacific colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
Table 18 Japan colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 19 China colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 20 India colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 21 Australia colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 22 Thailand colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 23 South Korea colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 24 Latin America colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 25 Latin America colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
Table 26 Brazil colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 27 Mexico colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 28 Argentina colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 29 Middle East and Africa colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 30 Middle East and Africa colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
Table 31 South Africa colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 32 Saudi Arabia colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 33 UAE colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 34 Kuwait colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Colorectal cancer therapeutics: Market outlook
Fig. 9 Colorectal cancer therapeutics: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Colorectal cancer therapeutics market driver impact
Fig. 15 Colorectal cancer therapeutics market restraint impact
Fig. 16 Colorectal cancer Therapeutics market strategic Initiatives analysis
Fig. 17 Colorectal cancer therapeutics market: Drug class movement analysis
Fig. 18 Colorectal cancer therapeutics market: Drug class outlook and key takeaways
Fig. 19 Immunotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Other market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Global Colorectal Cancer Therapeutics market: Regional Movement Analysis
Fig. 23 Global Colorectal cancer therapeutics market: Regional outlook and key takeaways
Fig. 24 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Companies Mentioned

  • Amgen, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Lilly
  • Merck & co., Inc.
  • F. Hoffmann-La Roche Ltd
  • Sanofi

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedSeptember 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 11.5 Billion
Forecasted Market Value ( USD ) by 2030 $ 16.7 Billion
Compound Annual Growth Rate4.7%
Regions CoveredGlobal
No. of Companies Mentioned7

Related Topics

Related Reports

Colorectal Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Colorectal Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 172 Pages
  • Global
From
Colorectal Cancer Therapeutics: Global Strategic Business Report - Product Image

Colorectal Cancer Therapeutics: Global Strategic Business Report

  • Report
  • 363 Pages
  • Global
From
Global Colorectal Cancer Therapeutics Market Report and Forecast 2023-2031 - Product Image

Global Colorectal Cancer Therapeutics Market Report and Forecast 2023-2031

  • Report
  • 160 Pages
  • Global
From
Colorectal Cancer Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Colorectal Cancer Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 135 Pages
  • Global
From
Global Colorectal Cancer Drugs Market by Drug Class (Anti-angiogenic Drugs, Chemotherapy Drugs, Immunotherapy Drugs), Treatment Type (First-Line Treatment, Second-Line Treatment, Third-Line Treatment and Beyond), Route of Administration, Distribution Channel - Forecast 2024-2030 - Product Image

Global Colorectal Cancer Drugs Market by Drug Class (Anti-angiogenic Drugs, Chemotherapy Drugs, Immunotherapy Drugs), Treatment Type (First-Line Treatment, Second-Line Treatment, Third-Line Treatment and Beyond), Route of Administration, Distribution Channel - Forecast 2024-2030

  • Report
  • 196 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.